Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Role of Cxcl12/Cxcr4/Cxcr7 Axis in Cognitive Impairment Associated With Neurodegenerative Diseases Publisher



Sarallah R1 ; Jahani S2 ; Soltani Khaboushan A3 ; Moaveni AK3 ; Amiri M3 ; Majidi Zolbin M3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Islamic Azad University, Tehran, Iran
  2. 2. MS Research Center Neuroscience Institute, Tehran University of Medical Science, Iran
  3. 3. Pediatric and Urology and Regenerative Medicine Research Center, Gene, Cell and Tissue Research Institute, Children Medical Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Brain, Behavior, and Immunity - Health Published:2025


Abstract

Neurodegenerative diseases, including Alzheimer's Disease (AD), Parkinson's Disease (PD), Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS), are characterized by progressive neuronal loss and cognitive impairment (CI). The: Cysteine-X-cysteine chemokine ligand 12(CXCL12)/CXC chemokine receptor type 4 (CXCR4)/CXC chemokine receptor type 7 (CXCR7) axis has emerged as a critical molecular pathway in the development of CI in these disorders. This review explores the role of this axis in the pathogenesis of CI across these neurodegenerative diseases, synthesizing current evidence and its implications for targeted therapies. In AD, dysregulation of this axis contributes to amyloid-β accumulation and tau hyperphosphorylation, leading to synaptic dysfunction and cognitive decline. PD studies reveal that CXCL12/CXCR4 signaling influences dopaminergic neuron survival and microglial activation, affecting cognitive function. In MS, the axis modulates neuroinflammation and demyelination processes, impacting cognitive performance. ALS research indicates that the CXCL12/CXCR4/CXCR7 pathway is involved in motor neuron degeneration and associated cognitive deficits. Across these diseases, the axis influences neuroinflammation, synaptic plasticity, and neuronal survival through various signaling cascades, including PI3K/AKT, MAPK, and JAK/STAT pathways. Emerging evidence suggests that modulating this axis could provide neuroprotective effects and potentially alleviate cognitive symptoms. This review highlights the potential of the CXCL12/CXCR4/CXCR7 axis as a therapeutic target for addressing CI in neurodegenerative diseases. It also underscores the need for further research to fully elucidate its role and develop effective interventions, potentially leading to improved clinical management strategies for these devastating disorders. © 2024 The Authors
Related Docs
View other Related Docs
1. Combined Effects of Pioglitazone and Doxorubicin on Migration and Invasion of Mda-Mb-231 Breast Cancer Cells, Journal of the Egyptian National Cancer Institute (2022)
2. The Dialogue Between Neuroinflammation and Adult Neurogenesis: Mechanisms Involved and Alterations in Neurological Diseases, Molecular Neurobiology (2023)
3. Neuroprotective Effects of Ellagic Acid on Cuprizone-Induced Acute Demyelination Through Limitation of Microgliosis, Adjustment of Cxcl12/Il-17/Il-11 Axis and Restriction of Mature Oligodendrocytes Apoptosis, Pharmaceutical Biology (2017)
4. Cognitive Deficits in Multiple Sclerosis: Auditory and Visual Attention and Inhibitory Control, Applied Neuropsychology: Adult (2025)
5. Quantitative Susceptibility Mapping in Amyotrophic Lateral Sclerosis: Automatic Quantification of the Magnetic Susceptibility in the Subcortical Nuclei, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (2025)
6. A Novel Approach to Type 3 Diabetes Mechanism: The Interplay Between Noncoding Rnas and Insulin Signaling Pathway in Alzheimer's Disease, Journal of Cellular Physiology (2022)
7. Emerging Role of Mesenchymal Stromal Cells (Mscs)-Derived Exosome in Neurodegeneration-Associated Conditions: A Groundbreaking Cell-Free Approach, Stem Cell Research and Therapy (2022)
8. Pathological Aging of Patients With Amyotrophic Lateral Sclerosis: A Preliminary Longitudinal Study, Brain and Behavior (2025)
Experts (# of related papers)
View all Related Experts
Mohammad Ali Sahraian (4)
Farzad Fatehi (2)
Other Related Docs
9. Prevalence of Cognitive Impairment (Ci) in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Caspian Journal of Internal Medicine (2024)
10. Activation and Regulation of Nlrp3 Inflammasome by Intrathecal Application of Sdf-1A in a Spinal Cord Injury Model, Molecular Neurobiology (2016)
11. Advanced Nanoparticle Strategies for Optimizing Rna Therapeutic Delivery in Neurodegenerative Disorders, Biomedicine and Pharmacotherapy (2024)
12. Cognitive Deficits in Multiple Sclerosis: Auditory and Visual Attention and Inhibitory Control, Applied Neuropsychology:Adult (2023)
13. Changes in Dna Methylation in Apoe and Ackr3 Genes in Multiple Sclerosis Patients and the Relationship With Their Heavy Metal Blood Levels, NeuroToxicology (2021)
14. A Focus on Allogeneic Mesenchymal Stromal Cells As a Versatile Therapeutic Tool for Treating Multiple Sclerosis, Stem Cell Research and Therapy (2021)
15. T1 and T2 Weighted Lesions and Cognition in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Journal of Clinical Neuroscience (2024)
16. The Association of Sdf-1 and Cxcr4 Gene Polymorphisms With Rheumatoid Arthritis Susceptibility in the Iranian Population, Human Gene (2025)
17. Comparing Cognitive Impairment Using Macfims in Patients With Multiple Sclerosis and Healthy Controls: A Systematic Review and Meta-Analysis, BMC Neurology (2024)